.Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AN01_Lithium.Lithium

Information

name:Lithium
ATC code:N05AN01
route:oral
n-compartments1

Lithium is a mood stabilizer primarily used in the treatment and prophylaxis of bipolar disorder and, to a lesser extent, depression. It is an approved drug with established efficacy for the prevention of manic and depressive episodes in bipolar disorder. Lithium is also sometimes used off-label for other psychiatric conditions.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adults after oral administration of lithium carbonate.

References

  1. Yuan, J, et al., & Zhu, C (2021). Population Pharmacokinetics of Lithium in Young Pediatric Patients With Intellectual Disability. Frontiers in pharmacology 12 650298–None. DOI:10.3389/fphar.2021.650298 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33935755

  2. Yamaguchi, D, et al., & Kamimura, H (2019). Population Pharmacokinetics and Exposure-Response of Lithium Carbonate in Patients Based on Tubular Reabsorption Mechanisms. European journal of drug metabolism and pharmacokinetics 44(3) 329–338. DOI:10.1007/s13318-018-0536-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30536114

  3. Findling, RL, et al., & Jusko, WJ (2010). First-dose pharmacokinetics of lithium carbonate in children and adolescents. Journal of clinical psychopharmacology 30(4) 404–410. DOI:10.1097/JCP.0b013e3181e66a62 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20531219

Revisions


Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos